HOME >> BIOLOGY >> NEWS
Sidebar: new trial should lead to better understanding of why exercise is an effective treatment for depression

DURHAM, N.C. -- The Duke University Medical Center researchers who found evidence that exercise can be an effective treatment for major depression are embarking on a larger trial they believe will answer some of the remaining questions posed by their earlier results.

The new trial, which is being funded by a $3 million grant from the National Institute of Mental Health, is designed to further refine which depressed patients can benefit from exercise and determine why exercise appears to be effective. Additionally, the study will measure the effect of exercise on a phenomenon known as vascular depression, a form of depression that appears linked to actual abnormalities in blood vessels of the brain, and not brain chemical imbalances. The previous Duke studies, led by psychologist James Blumenthal, found that exercise was just as effective as the most common anti-depressive medication in reducing the symptoms of major depression.

"This new trial is intended to answer some of the whys' posed by those original studies," Blumenthal explained. "We are very interested in evaluating behavioral, non-pharmacologic approaches to treating depression. Because up to one-third of depressed patients may not respond to drug therapy, and those who do take drugs may complain of side effects, it is important to find other approaches."

Over the next five years, the researchers plan to enroll 216 volunteers, half of whom will be assigned randomly to the drug arm of the trial and half to the exercise arm. The drug to be used is sertraline (trade name Zoloft), a member of a class of commonly used anti-depressants known as selective serotonin reuptake inhibitors, and the same drug used in the earlier trials.

Unlike the earlier trials, the new trial will have a placebo, or ineffective sugar pill, arm. Also unlike the earlier trials, the exercise arm will be divided as well -- half of the patients will do thei
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
20-Sep-2000


Page: 1 2 3

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
(Date:12/7/2016)... , Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dr. Dan Kephart as its chief science ... will assume his responsibilities at Neogen effective Jan. 1. ... director for the agribusiness unit of Thermo Fisher Scientific, ... at Life Technologies. His extensive industry experience also includes ...
Breaking Biology Technology:
Cached News: